The use of TRM cells as a predictive biomarker of the response to immunotherapies has been also documented in urothelial cancer and NSCLC patients harboring tumors with high levels of ITGAE transcripts treated with anti-PD-L1 (126). This evidence concerns the gene CD274 and non-small cell lung carcinoma.